Prevalence of co-trimoxazole induced hyperkalemia in chronic and acute users in a tertiary teaching hospital. by Moustafa, Rana et al.
JASSIM, Z., MOUSTAFA, R. and AZIZ, H.A. 2016. Prevalence of co-trimoxazole induced hyperkalemia in chronic and 
acute users in a tertiary teaching hospital. Presented at 2016 Qatar Foundation annual research conference (ARC 16), 





This document was downloaded from 
https://openair.rgu.ac.uk 
Prevalence of co-trimoxazole induced 
hyperkalemia in chronic and acute users in a 
tertiary teaching hospital. 
JASSIM, Z., MOUSTAFA, R. and AZIZ, H.A. 
2016 
PREVALENCE OF CO-TRIMOXAZOLE INDUCED HYPERKALEMIA IN CHRONIC AND ACUTE USERS IN A
TERTIARY TEACHING HOSPITAL
Figure 1.  Average of Potassium Level for QD 
& EOD over different duration
Objective  
•Primary: evaluate the risk of  
hyperkalemia in patients receiving 
cotrimoxazole.
•Secondary: 
1) detect the changes of potassium level 
from baseline to 7, 14, 21, and 30 days
2) determine the association between co-
trimoxazole dose and potassium level
3) examine the relationship between 
renal function and hyperkalemia
Method 
•A retrospective observation study of all 
patients treated with cotrimoxazole during 
Jan 2012 till Jan 2013. 
•Exclusion criteria include patients 
received less than 2 doses or have no lab 
test.
• Patient’s medical records (both electronic 
and paper-based) were used to collect 
required data. 
•Data analyzed using descriptive & 
inferential analyses.
o 161 patients were included in this study.
Patients were taking cotrimoxazole either
as once daily (47%) or every other day
(53%).
o Co-trimoxazole was taken at doses:
480mg (19.1%), 960mg (66%), and 1920mg
(14.9%).
o Eighty-nine patients (55.3%) were taking
other concomitant medications that may
also increase potassium level (i.e. ACE-I
and B-blocker). Figure 2
o Around 26% of the patients treated with
co-trimoxazole developed Hyperkalemia
during the observed time (42 out of 161
patients).
Conclusion
Although many patients taking co-
trimoxazole developed
Hyperkalemia, the effect of renal 
function and use of other concomitant 
medications can’t be ignored
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Results (contd.)  
o There was no significant correlation 
between cotrimoxazole doses and 
hyperkalemia (25.9% in 480mg, 31.2% in 
960 and 28.6% in 1920mg; p=0.863) in 
each dose group, however, 82.5% of 
hyperkalemia cases were associated 
with significant increase in serum 
creatinine (p=0.00).
o The highest mean change of 
potassium level in once daily dosing 
was at “baseline-7 days” interval, 
while it was highest at “baseline-30 
days” interval in every other day 
dosing. However; none of the changes 
from baseline to 7, 14, 21 and 30 days 
was found to be significant. Figure 3























Figure 3. Change in  K level from baseline 
to 7, 14, 21 and 30 days
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